Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 127,539 | 115,779 | 108,963 | 167,171 | 191,778 |
| Marketable Securities | 224,428 | 221,894 | 214,679 | 133,506 | 171,566 |
| Receivables | 78,734 | 77,682 | 82,606 | 73,540 | 68,378 |
| Inventories | 91,741 | 83,778 | 79,761 | 78,662 | 75,441 |
| Other current assets | 31,747 | 22,775 | 14,422 | 14,848 | 13,104 |
| TOTAL | $554,189 | $521,908 | $500,431 | $467,727 | $520,267 |
| Non-Current Assets | |||||
| PPE Net | 213,755 | 212,620 | 203,949 | 199,141 | 182,099 |
| Investments And Advances | 90,116 | 118,085 | 129,937 | 170,290 | 128,957 |
| Intangibles | 157,968 | 118,345 | 117,776 | 64,699 | 25,456 |
| Other Non-Current Assets | 228,505 | 14,558 | 14,112 | 15,306 | 12,578 |
| TOTAL | $690,344 | $463,608 | $465,774 | $449,436 | $349,090 |
| Total Assets | $1,244,533 | $985,516 | $966,205 | $917,163 | $869,357 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 92,097 | 83,930 | 78,541 | 78,068 | 63,921 |
| TOTAL | $92,097 | $83,930 | $78,699 | $78,154 | $64,070 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 0 | 158 | 86 | 149 |
| Other Non-Current Liabilities | 566,772 | 538,624 | 542,266 | 516,824 | 501,434 |
| TOTAL | $566,772 | $538,624 | $542,266 | $516,824 | $501,434 |
| Total Liabilities | $658,869 | $622,554 | $620,965 | $594,978 | $565,504 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 102,497 | 102,059 | 101,627 | 101,131 | 100,730 |
| Common Shares | 103 | 102 | 102 | 101 | 101 |
| Retained earnings | -359,076 | -576,410 | -575,933 | -577,084 | -581,795 |
| Other shareholders' equity | -3,757 | 7,909 | 3,333 | -782 | -2,419 |
| TOTAL | $585,664 | $362,962 | $345,240 | $322,185 | $303,853 |
| Total Liabilities And Equity | $1,244,533 | $985,516 | $966,205 | $917,163 | $869,357 |